Minerva

Trial predictability and other stories . . .

BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f5444 (Published 11 September 2013) Cite this as: BMJ 2013;347:f5444

Trials inevitably mean tribulations. Randomised controlled trials require effort and time, and their moral basis depends on genuine uncertainty about the value of the intervention being tested. A classic short paper in Nature (2013, doi:10.1038/500395a) by Djulbegovic and colleagues examines how often randomised controlled trials show that a new intervention is superior to its comparator. The researchers analysed 860 published and unpublished phase III trials performed by academics or pharmaceutical companies in six consecutive series of trials with a total of more than 350 000 patients. They found that new treatments were shown to be superior in around 50% of cases—just as one would predict from the principle of clinical equipoise. They conclude that “our retrospective view of more than 50 years of randomized trials shows that they remain the ‘indispensable ordeals’ through which biomedical researchers’ responsibility to patients and the public is manifested.”

While randomised controlled trials remain the best test of individual treatments, Minerva believes that …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe